Butoconazole
- Atc Codes:G01AF15
- CAS Codes:64872-77-1#64872-76-0
- PHARMGKB ID:64872-77-1#64872-76-0
Table of contents
- Brand Names
- Chemistry
- Pharmacologic Category
- Mechanism of Action
- Therapeutic Use
- Pregnancy and Lactation Implications
- Contraindications
- Warnings and Precautions
- Adverse Reactions
- Toxicological Effects
- Drug Interactions
- Dosage
- Pharmacokinetics and Pharmacodynamics
Brand Names
Europe
Belgium: Gynomyk; Bulgaria: Gynazol; France: Gynomyk; Hungary: Gynazol; Netherlands: Gynomyk; Slovakia: Gynazol.
North America
Canada: Femstat, Gynazole; USA: Femstat, Gynazole.
Latin America
Brazil: Gynazole.
Drug combinations
Chemistry
Butoconazole Nitrate: C~19~H~17~Cl~3~N~2~S HNO~3~. Mw: 474.79. (1) 1H-Imidazole, 1-[4-(4-chlorophenyl)-2-[(2,6-dichlorophenyl)thio]butyl]-, mononitrate, (±)-; (2)(±)-1-[4-(p-Chlorophenyl)-2-[(2,6-dichlorophenyl)thio]butyl]imidazole mononitrate. CAS-64872-77-1; CAS-64872-76-0 (butoconazole)(1978).
Pharmacologic Category
Antifungals; Azoles, Vaginal. (ATC-Code: G01AF15).
Mechanism of action
Imidazole-derivative azole antifungal. Increases cell membrane permeability in susceptible fungi. Usually fungistatic in action; can be fungicidal at high concentrations or against very susceptible organisms (e.g. Candida). Presumably exerts its antifungal activity by altering cellular membranes, resulting in increased membrane permeability, secondary metabolic effects, and growth inhibition. Interferes with ergosterol synthesis probably via inhibition of C-14 demethylation of sterol intermediates (e.g. lanosterol). Spectrum of antifungal activity includes many fungi (active in vitro and in vivo against C. albicans, C. glabrata, and C. tropicalis; active in vitro against Trichophyton concentricum, T. mentagrophytes, T. rubrum, T. tonsurans, Epidermophyton floccosum, Microsporum canis, M. gypseum, Aspergillus and Cryptococcus), and some Gram-positive bacteria (active in vitro against Staphylococcus aureus, Enterococcus faecalis (formerly Streptococcus faecalis), and S. pyogenes).
Therapeutic use
Local treatment of vulvovaginal candidiasis.
Pregnancy and lactiation implications
Use should be limited to the 2^nd^ or 3^rd^ trimesters, and only if the potential benefits justify the possible risks to the fetus. Use caution during lactation.
Unlabeled use
Contraindications
Hypersensitivity to butoconazole or any component of the formulation.
Warnings and precautions
Irritation or sensitization might occur. Contains mineral oil which may weaken latex or rubber products (condoms, vaginal contraceptive diaphragms). HIV infection should be considered in sexually-active women with difficult-to-eradicate recurrent vaginal yeast infections. Candida identified by culture in the absence of symptoms is not an indication for antifungal treatment.